Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.

Baril JG, Angel JB, Gill MJ, Gathe J, Cahn P, van Wyk J, Walmsley S.

PLoS One. 2016 Feb 5;11(2):e0148231. doi: 10.1371/journal.pone.0148231. eCollection 2016. Review.

2.

Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.

de Waal R, Cohen K, Maartens G.

PLoS One. 2013 May 28;8(5):e63623. doi: 10.1371/journal.pone.0063623. Print 2013. Review.

3.

New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Bonnet E.

HIV AIDS (Auckl). 2010;2:167-78. doi: 10.2147/HIV.S13429. Epub 2010 Sep 17.

4.

Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

Melzi S, Carenzi L, Cossu MV, Passerini S, Capetti A, Rizzardini G.

Cholesterol. 2010;2010:271504. doi: 10.1155/2010/271504. Epub 2010 Oct 31.

5.

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, Tien PC, Bacchetti P, Shlipak M, Scherzer R; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM).

AIDS. 2010 Jul 17;24(11):1717-26. doi: 10.1097/QAD.0b013e32833ac7a2.

6.

Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Jacobson DL, Lindsey JC, Gordon CM, Moye J, Hardin DS, Mulligan K, Aldrovandi GM; Pediatric AIDS Clinical Trials Group P1045 team.

AIDS. 2010 Mar 13;24(5):687-96. doi: 10.1097/QAD.0b013e328336095d.

7.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, Ristola M, van Eeden A, Danner SA, Reiss P; MEDICLAS study group.

PLoS One. 2009 May 21;4(5):e5647. doi: 10.1371/journal.pone.0005647.

8.

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, Yarasheski K, Berzins B, Owens S, Forand J, Evans S, Murphy R.

J Antimicrob Chemother. 2009 May;63(5):998-1005. doi: 10.1093/jac/dkp071. Epub 2009 Mar 19.

9.

Cardiovascular complications in HIV management: past, present, and future.

Aberg JA.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):54-64. doi: 10.1097/QAI.0b013e31818ceaa4. Review. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.

10.

The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective.

Mutimura E, Crowther NJ, Stewart A, Cade WT.

J Cardiometab Syndr. 2008 Spring;3(2):106-10.

Supplemental Content

Support Center